Cleargate Bets on Healthcare Revenue Cycle with Fellow Health Buy

Cleargate Capital Partners closed a strategic investment in Fellow Health Partners, a revenue cycle management services provider that handles medical claims, coding, and billing for healthcare organizations nationwide. The deal marks Cleargate's latest push into healthcare services infrastructure — a sector seeing frantic consolidation as providers scramble to outsource increasingly complex back-office operations.

Fellow Health, based in Louisiana, operates across the full revenue cycle stack: patient access, health information management, medical coding, and accounts receivable. The company serves hospitals, physician groups, and specialty care centers dealing with the labyrinthine process of turning patient encounters into collected revenue. Financial terms weren't disclosed, but the deal gives Cleargate a platform in a market estimated north of $200 billion annually — and growing as healthcare systems increasingly offload RCM functions to third-party specialists.

The announcement, released June 15, positions Fellow Health as a consolidation vehicle. Cleargate, a Birmingham, Alabama-based firm managing over $3 billion, specializes in buy-and-build strategies in fragmented services markets. RCM fits the pattern: thousands of small providers, rising regulatory complexity, and healthcare organizations desperate to convert their back-office from cost center to optimized function.

"Fellow Health Partners has built a reputation for delivering measurable results in revenue cycle performance," Cleargate managing partner David Strickland said in the announcement. What he didn't say: the RCM sector is in the middle of a land grab, with private equity firms racing to build scale before pricing power shifts entirely to a handful of mega-platforms.

Healthcare revenue cycle management sounds like back-office drudgery. It is. But it's also the difference between a hospital collecting 95% of what it's owed versus 75%. That gap — measured in tens of millions for mid-sized health systems — explains why RCM providers have become acquisition bait for PE firms hunting predictable cash flows in essential services.

The revenue cycle starts when a patient schedules an appointment and ends when the provider collects payment — a process that can stretch months and involve dozens of handoffs between registration, clinical documentation, coding, claim submission, payer adjudication, and collections. Each step introduces errors, denials, and revenue leakage. Fellow Health's pitch is simple: we do this for a living, you don't.

The market's been growing for a decade, but three forces accelerated consolidation recently. First, payer complexity exploded. The shift to value-based care, prior authorization requirements, and constant coding updates (ICD-10 alone added 55,000 diagnosis codes) turned billing into a specialized discipline that in-house teams struggle to keep current. Second, labor shortages hit healthcare administration hard — certified medical coders are expensive and scarce. Outsourcing became the path of least resistance.

Third, technology created a wedge. RCM providers that invested in automation, AI-powered coding assistance, and predictive denial management can deliver materially better results than legacy in-house departments. Fellow Health's competitive advantage, according to the company, rests on proprietary workflows and tech-enabled service delivery. Whether that's differentiated IP or just competent execution with modern software is harder to verify from the outside.

Cleargate Capital has run this script before. The firm targets lower-mid-market services businesses — typically $10M to $75M in revenue — with strong customer retention and predictable economics, then bolts on acquisitions to build regional or vertical scale. Previous Cleargate platforms include industrial services, business process outsourcing, and specialty distribution.

Fellow Health fits the mold. Founded in 2011, the company's grown organically by serving community hospitals and physician groups in markets where national RCM giants often underprice or over-promise. The company claims "measurable improvements in cash flow, claim acceptance rates, and compliance" — RCM-speak for "we get you paid faster with fewer denials." Exact financials weren't disclosed, but companies Cleargate backs at this stage typically run $20M–$50M in revenue with EBITDA margins in the high teens to low twenties.

The buy-and-build thesis is straightforward. RCM is hyper-fragmented: hundreds of small firms serving local or specialty niches, most founder-owned, many ready to sell as regulatory burdens increase and exit multiples stay attractive. Cleargate's role is to provide capital for M&A, professionalize operations, and cross-sell services across a larger customer base. The bet is that a $100M revenue RCM platform commands a higher multiple than five $20M independents — and can deliver better margins through shared technology and overhead.

Source: Industry estimates compiled from HFMA, Black Book Market Research, Grand View Research. Figures represent U.S. outsourced RCM services market, 2025–2026.

Fellow Health's service lines span the full revenue cycle, but the real money's in three core functions. Medical coding — translating physician documentation into billable diagnosis and procedure codes — is the highest-margin piece, requiring certified specialists and constant training on payer-specific rules. Claims management involves scrubbing claims for errors before submission, managing denials, and resubmitting corrected claims to maximize reimbursement. Collections handles the patient responsibility portion, which has ballooned as high-deductible health plans shifted costs to consumers.

Cleargate's entry comes late to a crowded party. Private equity has been circling healthcare RCM for years, with notable recent deals including R1 RCM's $8.9 billion take-private by TowerBrook Capital Partners and Clayton, Dubilier & Rice in 2023, Waystar's combination with EQT-backed entities before its 2024 IPO, and Ensemble Health Partners' merger with Navihealth's RCM division under Clayton, Dubilier & Rice.

Those mega-deals created national platforms serving the largest health systems. The opportunity Cleargate's chasing sits one tier down: regional and specialty RCM providers serving mid-sized hospitals, ambulatory surgery centers, and physician groups that don't want to be the smallest client at a billion-dollar platform. The strategy is classic barbell arbitrage — avoid competing with R1 and Optum for enterprise contracts, instead build density in underserved segments.

The risk is that the mid-market gets squeezed. As national platforms push downmarket and automation reduces the labor arbitrage that made small RCM firms viable, the window for building a defensible regional player may be narrowing. Cleargate's betting it can move fast enough to create a business worth selling to a strategic or larger platform in three to five years.

Fellow Health's management, led by CEO Jason Clavelle, stays in place post-transaction — standard for Cleargate deals, which typically keep founder-operators on board with meaningful equity rollovers. Clavelle and his team presumably have targets: double revenue in 36 months, complete 8–12 add-on acquisitions, build a tech stack that supports 50% more volume without proportional headcount growth.

Whether they can execute depends on finding sellers, integrating acquisitions without losing customers, and avoiding the operational chaos that sinks roll-ups when growth outpaces systems. In RCM, integration risk is real — bolt on the wrong coding shop with sloppy quality controls and you inherit their denial rates, tanking metrics across the platform.

Every RCM provider talks about technology. Most still run on armies of offshore coders in the Philippines and India, with AI tools acting as assistive layers rather than replacements. The economics work — for now. Offshore certified coders cost 40%–60% less than U.S. equivalents, and clients care about accuracy and turnaround time more than where the work gets done.

But the labor model's under pressure. Generative AI coding assistants are hitting 85%+ accuracy on routine encounters, and ambient documentation tools are capturing clinical data without physicians manually entering it. If automation reaches 95% accuracy in the next 18–24 months — a realistic timeline based on current trajectories — the labor arbitrage disappears. At that point, RCM becomes a software business with services attached, not a services business with software tools. That shift favors scaled players with tech investment budgets, not sub-$50M independents.

Fellow Health likely traded at 8x–12x EBITDA based on comparable recent RCM transactions in the lower-mid-market. That's a healthy multiple for a services business with recurring revenue but no proprietary tech moat. It also suggests Cleargate sees a path to 14x–18x on exit — achievable if they double EBITDA and multiples hold or expand.

The valuation environment for healthcare services remains resilient despite broader PE market jitters. Healthcare is non-discretionary, RCM revenue is tied to patient volumes rather than elective spending, and providers aren't bringing these functions back in-house — the talent and tech investment required makes that a non-starter. As long as those conditions hold, RCM platforms will find buyers.

The wildcard is regulatory change. If CMS simplifies billing requirements or mandates interoperability that reduces claim errors, the value of RCM services could compress. Conversely, if regulatory complexity continues its 30-year upward march, outsourcing becomes even more essential. Betting on continued complexity in U.S. healthcare reimbursement is historically a safe wager.

Cleargate's investment thesis also assumes M&A targets stay available. In fragmented services markets, the first platform to achieve regional density often scoops up the best assets, leaving followers to overpay for second-tier acquisitions or integrate problem companies that couldn't sell to anyone else. Fellow Health's head start in the Southeast — Louisiana and surrounding states — gives them a geographic anchor, but national consolidation means they'll be competing with better-capitalized buyers for every deal.

Cleargate Capital, founded in 2010, operates in the unglamorous middle of the PE market: companies too small for mega-funds, too complex for search funds, often family-owned and looking for a first institutional partner. The firm's portfolio includes industrial distribution, environmental services, IT solutions, and specialty manufacturing — all sectors where fragmentation creates buy-and-build opportunities.

The firm's performance data isn't public, but Cleargate has completed multiple fund cycles and continued raising capital, which suggests returns met or exceeded investor expectations. Their model — patient capital, founder-friendly deal structures, operational support rather than financial engineering — works best when markets reward execution over leverage. In today's higher-rate environment, that's an advantage. Companies that grow EBITDA through M&A and organic improvement can still generate strong returns even if exit multiples don't expand.

RCM providers face a structural risk that doesn't show up in pitch decks: customer concentration. A typical $30M RCM firm might serve 15–25 clients, but the top five often represent 60%+ of revenue. Lose one large hospital contract — because they got acquired, brought billing in-house, or switched to a competitor — and you've just wiped out 15%–20% of EBITDA. That risk compounds during roll-ups when integration distracts leadership and service quality slips.

Fellow Health's customer base wasn't detailed in the announcement, but community hospitals and physician groups are undergoing their own consolidation wave. As independent hospitals join health systems and private practices get acquired by hospital networks or PE-backed physician platforms, RCM contracts get renegotiated or consolidated. A client that generated $2M annually can disappear overnight when their new corporate parent mandates a different RCM vendor.

The playbook to mitigate this is well-known: diversify client base, move upmarket to sticky enterprise contracts, or go vertical into specialties where switching costs are higher (behavioral health, ambulatory surgery, specialty physician groups). Whether Cleargate and Fellow Health execute that diversification fast enough to offset natural customer churn is the bet.

Another underappreciated risk: payer consolidation. As UnitedHealth, CVS, Cigna, and Elevance continue absorbing market share, the number of payers RCM firms deal with shrinks — and those mega-payers have negotiating leverage to demand tighter billing timelines, more detailed documentation, and faster adjudication. That squeezes RCM margins unless providers can automate enough to absorb the extra work without adding headcount.

The immediate roadmap is predictable. Cleargate will inject capital for technology upgrades — probably investments in AI coding assistants, robotic process automation for claims scrubbing, and patient payment portals. They'll also fund add-on acquisitions, likely targeting competitors in adjacent geographies or specialized RCM firms in high-margin verticals like orthopedics or cardiology.

Fellow Health will professionalize: upgraded finance systems, salesforce buildout, formalized integration playbooks. The company will probably hire a chief technology officer if they don't already have one, and will start attending industry conferences not as a vendor but as a platform looking to acquire. Organic growth targets will likely sit around 10%–15% annually, with M&A adding another 20%–30% to the top line each year.

Source: Typical PE-backed RCM platform growth model based on industry benchmarks and comparable platform builds, 2020–2025.

The exit, assuming all goes well, probably happens in 2029–2030. Likely buyers include larger PE-backed RCM platforms looking to fill geographic gaps, strategic acquirers like Optum or R1 picking up regional density, or possibly a healthcare-focused permanent capital vehicle if those continue proliferating. A secondary sale to another mid-market PE firm is possible but less likely — by that point, Fellow Health will either be big enough to attract larger buyers or will have stalled out in a way that makes it unattractive.

Cleargate's bet on Fellow Health reflects a broader trend: mid-market PE firms are flooding into healthcare services, specifically the unglamorous infrastructure layer that makes the system run. Not telehealth apps, not AI diagnostics, not sexy biotech — billing, scheduling, credentialing, staffing. The stuff hospitals need but hate doing.

These businesses offer predictable cash flows, recurring revenue, defensive growth (healthcare spending doesn't contract much even in recessions), and fragmentation that creates M&A runways. They're also largely immune to reimbursement risk — RCM providers get paid a percentage of collections or a per-claim fee, so they're aligned with providers but not directly exposed to CMS rate cuts.

The appetite won't fade soon. As long as U.S. healthcare remains Byzantine, and as long as providers prioritize clinical outcomes over back-office efficiency, outsourcing will grow. The question is whether returns hold up as more capital chases the same assets. RCM multiples have already climbed from 6x–8x EBITDA in 2018 to 9x–13x today for quality platforms. If that expansion continues, expect IRRs to compress — or for firms like Cleargate to get more creative about where and how they source deals.

One thing's certain: healthcare's back office is becoming private equity's front office. Fellow Health is just the latest proof point.

Cleargate and Fellow Health now face the classic roll-up dilemma: grow fast enough to justify the entry multiple and create a business worth selling, but not so fast that integration breaks and service quality collapses. In RCM, that balance is particularly precarious because the product is service delivery — if claim denial rates spike or coding accuracy drops during an integration, customers notice immediately and contracts get pulled.

The next 12–18 months will reveal the playbook. If Fellow Health closes 2–3 add-ons by mid-2027 and revenue crosses $75M–$100M without customer churn spiking, Cleargate's thesis is working. If they struggle to find accretive deals or if the first integration goes sideways, they'll spend the rest of the hold period repairing instead of building.

The announcement itself reveals nothing about execution capability — it's a press release, not a performance report. But the market dynamics are clear: RCM consolidation is accelerating, automation is reshaping labor economics, and the window for building a valuable mid-market platform is finite. Cleargate made the bet. Now comes the harder part: delivering on it.

For now, Fellow Health joins a crowded field of PE-backed RCM platforms racing to reach scale before the music stops. Whether they're still dancing when it does depends on deals we won't see announced for another year — and operational execution that never makes it into press releases at all.